Importantly, insulin sensitizer treatment restored the amplitude of GnRH-stimulated LH pulses to control levels, suggesting that this neuroendocrine defect is largely secondary to perturbations in insulin-glucose homeostasis as reported in PCOS women. The gene discussed is GNRH1; the disease is polycystic ovary syndrome.